GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InDex Pharmaceuticals Holding AB (OSTO:INDEX) » Definitions » Cash Ratio

InDex Pharmaceuticals Holding AB (OSTO:INDEX) Cash Ratio : 6.19 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is InDex Pharmaceuticals Holding AB Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. InDex Pharmaceuticals Holding AB's Cash Ratio for the quarter that ended in Mar. 2024 was 6.19.

InDex Pharmaceuticals Holding AB has a Cash Ratio of 6.19. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for InDex Pharmaceuticals Holding AB's Cash Ratio or its related term are showing as below:

OSTO:INDEX' s Cash Ratio Range Over the Past 10 Years
Min: 0.06   Med: 7.61   Max: 54.6
Current: 6.19

During the past 10 years, InDex Pharmaceuticals Holding AB's highest Cash Ratio was 54.60. The lowest was 0.06. And the median was 7.61.

OSTO:INDEX's Cash Ratio is ranked better than
69.99% of 1503 companies
in the Biotechnology industry
Industry Median: 2.94 vs OSTO:INDEX: 6.19

InDex Pharmaceuticals Holding AB Cash Ratio Historical Data

The historical data trend for InDex Pharmaceuticals Holding AB's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InDex Pharmaceuticals Holding AB Cash Ratio Chart

InDex Pharmaceuticals Holding AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.61 5.24 40.55 23.41 5.00

InDex Pharmaceuticals Holding AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.56 9.61 8.49 5.00 6.19

Competitive Comparison of InDex Pharmaceuticals Holding AB's Cash Ratio

For the Biotechnology subindustry, InDex Pharmaceuticals Holding AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InDex Pharmaceuticals Holding AB's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InDex Pharmaceuticals Holding AB's Cash Ratio distribution charts can be found below:

* The bar in red indicates where InDex Pharmaceuticals Holding AB's Cash Ratio falls into.



InDex Pharmaceuticals Holding AB Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

InDex Pharmaceuticals Holding AB's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=294.267/58.906
=5.00

InDex Pharmaceuticals Holding AB's Cash Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash Ratio (Q: Mar. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=269.824/43.591
=6.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InDex Pharmaceuticals Holding AB  (OSTO:INDEX) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


InDex Pharmaceuticals Holding AB Cash Ratio Related Terms

Thank you for viewing the detailed overview of InDex Pharmaceuticals Holding AB's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


InDex Pharmaceuticals Holding AB (OSTO:INDEX) Business Description

Traded in Other Exchanges
N/A
Address
Berzelius vag 13, Solna, SWE, 171 65
InDex Pharmaceuticals Holding AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The company's main asset is the drug candidate cobitolimod, which is being evaluated in the phase III study as a treatment for moderate to severe ulcerative colitis - a disabling, chronic inflammation of the colon. It has also developed a platform of patent-protected substances, so-called DNA-based Immunomodulatory Sequences, with the potential to be used in the treatment of various immunological diseases.

InDex Pharmaceuticals Holding AB (OSTO:INDEX) Headlines

No Headlines